Recommendations for the diagnosis and treatment of chronic lymphocytic leukaemia

Czech version

Authors: L. Smolej ¹; M. Doubek ²; M. Špaček ³; R. Urbanová ⁴; P. Obrtlíková ³; J. Schwarz ⁵; D. Lysák ⁶; Š. Pospíšilová ²; M. Jarošová ⁴; S. Peková ⁷; T. Kozák ⁸
Authors‘ workplace: IV. interní hematologická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Karlovy Hradec Králové ¹
Published in: Transfuze Hematol. dnes,19, 2013, No. 2, p. 61-68.
Category: Comprehensive Reports, Original Papers, Case Reports

Add autoři: Česká skupina pro chronickou lymfocytární leukemii, sekce České hematologické společnosti České lékařské společnosti Jana Evangelisty Purkyně

Overview

Chronic lymphocytic leukaemia (CLL) is a disease with a remarkably heterogeneous clinical course. Because diagnosis and therapy must be tailored individually according to patient age, comorbidities and therapeutic gaols and as the understanding of CLL has been deepening at considerable speed, the Czech CLL Study Group, the working party of the Czech Haematological Society, has developed the following guidelines to facilitate the diagnostic and therapeutic decision-making process in clinical practice. These guidelines are based on a comprehensive analysis of current literature and follow the principles of evidence-based medicine.

Key words:
chronic lymphocytic leukaemia, diagnostics, treatment

Sources

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008; 111: 5446-5456.

2. Moreau EJ, Matutes E, A‘Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997; 108(4): 378-382.

3. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol 2011; 8(1): 38-47.

4. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl 6): vi50-54.

5. Ghia P, Stamatopoulos K, Belessi C, et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007; 21(1): 1-3.

6. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26(7): 1458-1461.

7. Oscier D, Dearden C, Erem E, et al. British Committee for Standards in Haematology. Guidelines on the diagnosis, investigation and management of Chronic Lymphocytic Leukaemia. Br J Haematol 2012; 159: 541-564.

8. Catovsky D. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239.

9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31-41.

10. Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008; 56(10): 1926-1931.

11. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376(9747): 1164-1174.

12. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114(16): 3382-3391.

13. Smolej L. Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. Curr Pharm Des. 2012; 18(23): 3399-3405.

14. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 2012; 159(1): 67-77.

15. Mauro FR, Bandini G, Barosi G, et al. SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leuk Res 2012; 36(4): 459-466.

16. Hillmen P. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.

17. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28(10): 1756-1765.

18. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99(10): 3554-3561.

19. Smolej L, Procházka V, Špaček M, et al. Doporučení pro léčbu alemtuzumabem u chronické lymfocytární leukémie (CLL). Vnitř Lék 2012; 58(3): 232-236.

20. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28(10): 1749-1755.

21. Smolej L. The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs 2012; 21(7): 1009-1017.

22. Smolej L, Doubek M, Panovska A, et al. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leuk Res 2012; 36(10): 1278-1282.

23. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29(26): 3559-3566.

24. Tonino SH, van Gelder M, Eldering E, van Oers MH, Kater AP. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia 2010; 24(3): 652-654.

25. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011; 12(13): 1204-1213.

26. Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30(9): 980-988.

27. Delgado J, Duarte RF. Practical aspects of allogeneic hematopoietic cell transplantation for patients with poor-risk chronic lymphocytic leukemia. ScientificWorldJournal 2011; 11: 161-172.

28. Montserrat E, Gribben JG. Autografting CLL: the game is over! Blood 2011; 117(23): 6057-6058.

29. Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009;27(1):1-10.

30. Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23(11): 1980-1988.

31. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43(2): 258-270.

32. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47(1): 8-32.

Labels

Haematology Internal medicine Clinical oncology

Separation of whole blood and gravity-based manufacturing of blood components by the disable set ErySet® with a hollow-fibre filter

A practical view of the role of HLA matching in unrelated donor haematopoietic stem cell transplantation

Clinical and biological prognostic factors in malignant lymphomas

Article was published in

Transfusion and Haematology Today

2013 Issue 2